Hemostasis via platelet aggregation enhancement

Hemostasis via platelet aggregation enhancement is a physiological process and therapeutic strategy aimed at arresting hemorrhage by promoting the formation of a platelet plug (StatPearls: Physiology, Platelets). This mechanism is not a single molecular target but a coordinated biological response involving multiple receptors, such as Glycoprotein IIb/IIIa and P2Y12, and ligands like von Willebrand factor (NCBI: Hemostasis and Thrombosis). In clinical medicine, the enhancement of this pathway is essential for treating acute bleeding episodes or underlying conditions like thrombocytopenia and von Willebrand disease (Mayo Clinic: Bleeding Disorders). Therapeutic agents that facilitate this process include thrombopoietin receptor agonists, which increase platelet production, and desmopressin, which increases the release of pro-coagulant factors (FDA: Eltrombopag Label). While effective for achieving hemostasis, the pharmacological stimulation of platelet aggregation carries significant risks, including pathological thrombosis and systemic thromboembolism (PubMed: Safety of Hemostatic Agents). Consequently, patients receiving these therapies must be closely monitored using biomarkers like platelet counts and thromboelastography to mitigate the risk of myocardial infarction or stroke.

Other names

Platelet aggregation promotionHemostatic platelet activationPro-coagulant platelet recruitment

Enhancement of platelet recruitment, activation, and cross-linking to form a stable primary hemostatic plug at the site of vascular injury.